{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:26:13Z","timestamp":1764433573837,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hypertension is a common risk factor for cardiovascular disease. Pharmacogenomics, as a tool for personalized healthcare, helps in determining the optimal drug treatment based on the genome of individual patient. This study reports a 49-year-old male with acute cerebral infarction, pulmonary infection, extremely high-risk hypertension (grade3), type 2 diabetes, hyperhomocysteinemia, hyperlipidemia, and fatty liver. The patient initially received conventional systemic treatment but continued to have severe hypertension (159\/85\u00a0mmHg). To better control blood pressure, a pharmacogenomic test was performed, and results showed that the SNP genotype of rs4961 (<jats:italic>ADD1<\/jats:italic>) suggests poor efficacy with certain antihypertensive drugs. The genotype of rs4149601 (<jats:italic>NEDD4L<\/jats:italic>) indicates better efficacy with hydrochlorothiazide, while the CYP3A5*3 genotype indicates a slow metabolism of calcium channel blockers, suggesting that amlodipine may be more effective than nifedipine. By replacing nifedipine with amlodipine and increasing the dosage of hydrochlorothiazide, the patient\u2019s systolic blood pressure was stabilized, although diastolic blood pressure remained suboptimal (131\/91\u00a0mmHg). Despite low potassium levels, the patient was not sensitive to spironolactone (141\/91\u00a0mmHg) but achieved exhibited well-controlled blood pressure (129\/90\u00a0mmHg) with hydrochlorothiazide, consistent with pharmacogenomics recommendations. In summary, pharmacogenomics testing identified genetic variations influencing the patient\u2019s response to specific drugs, guiding their selection and administration. This approach can lead to better blood pressure control and reduce the risk of adverse drug events, highlighting the potential of personalized drugs in managing hypertension through pharmacogenomics.<\/jats:p>","DOI":"10.3389\/fphar.2024.1424683","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:31:51Z","timestamp":1728361911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacogenomics assists in controlling blood pressure in cardiovascular and cerebrovascular patients during Rehabilitation: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Tian","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luhai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueran","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenbang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yipeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"B3","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/genes13071260","article-title":"Genetic contributors of efficacy and adverse metabolic effects of chlorthalidone in African Americans from the genetics of hypertension associated treatments (GenHAT) study","volume":"13","author":"Armstrong","year":"2022","journal-title":"Genes (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000258688","article-title":"CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease","volume":"31","author":"Bhatnagar","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review","volume":"328","author":"Carey","year":"2022","journal-title":"Jama"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/cm9.0000000000002028","article-title":"Ambulatory blood pressure monitoring for the management of hypertension","volume":"135","author":"Cheng","year":"2022","journal-title":"Chin. Med. J. Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/hyp.0000000000000203","article-title":"Medication adherence and blood pressure control: a scientific statement from the American heart association","volume":"79","author":"Choudhry","year":"2022","journal-title":"Hypertension"},{"key":"B8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2217\/pgs-2018-0191","article-title":"The future of pharmacogenetics in the treatment of hypertension","volume":"20","author":"Cunningham","year":"2019","journal-title":"Pharmacogenomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s0140-6736(97)01029-5","article-title":"Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension","volume":"349","author":"Cusi","year":"1997","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0440","article-title":"Hypertension and the kidneys","volume":"83","author":"De Bhailis","year":"2022","journal-title":"Br. J. Hosp. Med. (Lond)"},{"key":"B1","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/s0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5414\/cp202559","article-title":"CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation","volume":"55","author":"Huang","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.11909\/j.issn.1671-5411.2019.03.014","article-title":"2018 Chinese guidelines for prevention and treatment of hypertension-a report of the revision committee of Chinese guidelines for prevention and treatment of hypertension","volume":"16","year":"2019","journal-title":"J. Geriatr. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3109\/07853890.2011.653399","article-title":"Advancing management of hypertension through pharmacogenomics","volume":"44","author":"Johnson","year":"2012","journal-title":"Ann. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10741-018-09765-y","article-title":"Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review","volume":"24","author":"Johnson","year":"2019","journal-title":"Heart Fail Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2217\/pgs.13.161","article-title":"Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study","volume":"14","author":"Kamide","year":"2013","journal-title":"Pharmacogenomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clpt.2006.09.009","article-title":"Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects","volume":"80","author":"Kim","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/pharmaceutics13071100","article-title":"Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research","volume":"13","author":"Kvarnstr\u00f6m","year":"2021","journal-title":"Pharmaceutics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1161\/hypertensionaha.109.135103","article-title":"A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension","volume":"54","author":"Luo","year":"2009","journal-title":"Hypertension"},{"key":"B19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/hypertensionaha.108.113977","article-title":"Physiological interaction between alpha-adducin and WNK1-NEDD4L pathways on sodium-related blood pressure regulation","volume":"52","author":"Manunta","year":"2008","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e001854","DOI":"10.1161\/circgen.117.001854","article-title":"Genetic variants influencing plasma renin activity in hypertensive patients from the PEAR study (pharmacogenomic evaluation of antihypertensive responses)","volume":"11","author":"McDonough","year":"2018","journal-title":"Circ. Genom Precis. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018","volume":"324","author":"Muntner","year":"2020","journal-title":"Jama"},{"key":"B23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B25","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.clpt.2006.02.008","article-title":"Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects","volume":"79","author":"Park","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2023.12.026","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment practical approach","volume":"123","author":"Parodi","year":"2024","journal-title":"Eur. J. Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jacc.2011.08.061","article-title":"A common \u03b21-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation","volume":"59","author":"Parvez","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1524-6175.2002.01728.x","article-title":"Importance of potassium in cardiovascular disease","volume":"4","author":"Sica","year":"2002","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/HJH.0b013e3283410390","article-title":"A functional variant of the NEDD4L gene is associated with beneficial treatment response with \u03b2-blockers and diuretics in hypertensive patients","volume":"29","author":"Svensson-F\u00e4rbom","year":"2011","journal-title":"J. Hypertens."},{"key":"B31","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","article-title":"Pharmacogenetic factors affecting \u03b2-blocker metabolism and response","volume":"16","author":"Thomas","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/FPC.0b013e3283636822","article-title":"PharmGKB summary: diuretics pathway, pharmacodynamics","volume":"23","author":"Thorn","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/cir.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/jch.14236","article-title":"Non-pharmacological management of hypertension","volume":"23","author":"Verma","year":"2021","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.5414\/cp202211","article-title":"Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers","volume":"53","author":"Wang","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/hyp.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"unstructured":"Hypertension2018","key":"B37"},{"key":"B38","doi-asserted-by":"publisher","first-page":"CD001841","DOI":"10.1002\/14651858.CD001841.pub3","article-title":"First-line drugs for hypertension","volume":"4","author":"Wright","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/jhh.2013.67","article-title":"CYP3A5 polymorphism, amlodipine and hypertension","volume":"28","author":"Zhang","year":"2014","journal-title":"J. Hum. Hypertens."},{"key":"B40","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1038\/s41598-018-27377-2","article-title":"Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked mortality study","volume":"8","author":"Zhou","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1424683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T04:31:54Z","timestamp":1728361914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1424683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":40,"alternative-id":["10.3389\/fphar.2024.1424683"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1424683","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"article-number":"1424683"}}